Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice

Purpose: To describe the rationale and design of the VOYAGER (NCT05476926) study, which aims to investigate the safety and effectiveness of faricimab and the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in clinica...

Повний опис

Бібліографічні деталі

Автори:	Robyn Guymer, MBBS, PhD, Clare Bailey, MD, FRCP, Voraporn Chaikitmongkol, MD, Usha Chakravarthy, FRCOphth, PhD, Varun Chaudhary, MD, FRCS(C), Robert P. Finger, MD, PhD, Roberto Gallego-Pinazo, MD, PhD, Adrian Koh Hock Chuan, MBBS, MMed (Ophth), Susumu Ishida, MD, PhD, Monica Lövestam-Adrian, MD, PhD, Mariacristina Parravano, MD, Jose D. Luna Pinto, MD, Steffen Schmitz-Valckenberg, MD, Veeral Sheth, MD, MBA, Eric H. Souied, MD, PhD, Gloria C. Chi, PhD, MPH, Frank Gilberg, PhD, Carl Glittenberg, MD, Stefan Scheidl, MSc, PhD, Monica Bengus, MD
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2024-05-01
Серія:	Ophthalmology Science
Предмети:	Diabetic macular edema Faricimab Neovascular age-related macular degeneration Port Delivery System with ranibizumab Real-world study
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S2666914523001744
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!